Group 1 - The second meeting of the Supervisory Board of Yuekang Pharmaceutical Group Co., Ltd. was held on August 28, 2025, with all three supervisors present, complying with relevant laws and the company's articles of association [1] - The Supervisory Board approved the proposal regarding the company's 2025 semi-annual report and its summary, confirming that the report was prepared and reviewed in accordance with legal regulations and accurately reflected the company's situation [1] - The Supervisory Board also approved the special report on the storage and use of raised funds for the first half of 2025, affirming compliance with relevant regulations and confirming no misuse of funds [2]

Core Insights - The company reported a revenue of 1.17 billion yuan for the first half of 2025, with R&D investment amounting to 209 million yuan, representing 17.91% of revenue, an increase of 7.54 percentage points year-on-year [1] - The company has established eleven core technology platforms focusing on various drug types, including nucleic acid drugs and high-end traditional Chinese medicine, and has a pipeline of over twenty key projects [1] - As of June 30, 2025, the company has 42 R&D projects, including 21 innovative drugs and 21 generic drugs, and has accumulated 349 patents, with 21 new applications and 32 new patents granted in the first half of 2025 [1] R&D Progress - The company made significant advancements in key innovative drugs, with several products in the NDA review stage, including traditional Chinese medicine injections and other innovative formulations [2] - The company has successfully launched its small nucleic acid drug and mRNA vaccine R&D and pilot production platforms, which are now operating efficiently [2] - The company aims to focus on three major therapeutic areas: cardiovascular diseases, tumors, and infectious diseases, while continuing to develop a diverse pipeline through various methods such as independent R&D and collaborations [2]

Core Insights - The company reported a significant decline in revenue for the first half of 2025, with total revenue reaching 1.167 billion, representing a year-on-year decrease of 40.14% [1] - The net profit attributable to the parent company was negative at 98.8291 million, compared to a profit of 119 million in the same period last year [1] - The non-recurring net profit attributable to the parent company also showed a decline, amounting to negative 108 million, down from 117 million in the previous year [1]

证券代码：688658 证券简称：悦康药业 公告编号：2025-036 悦康药业集团股份有限公司 第二届监事会第十八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 二、监事会会议审议情况 （一）审议通过《关于公司<2025 年半年度报告及其摘要>的议案》 监事会认为：公司《2025 年半年度报告及其摘要》编制和审议程序符合法 律法规、《公司章程》和公司内部管理制度的各项规定；报告内容真实、准确、 完整，不存在任何虚假记载、误导性陈述或者重大遗漏，客观地反映了公司 2025 年半年度财务及经营状况。 表决结果：赞成票 3 票，反对票 0 票，弃权票 0 票。 具体内容详见公司于上海证券交易所网站（www.sse.com.cn）及指定媒体 披露的《悦康药业集团股份有限公司 2025 年半年度报告》及《悦康药业集团股 份有限公司 2025 年半年度报告摘要》。 （二）审议通过《关于<2025 年半年度募集资金存放与使用情况的专项报 告>的议案》 悦康药业集团股份有限公司（以下简称"公司"） ...

悦康药业集团股份有限公司2025 年半年度报告 公司代码：688658 公司简称：悦康药业 悦康药业集团股份有限公司 2025 年半年度报告 1 / 218 悦康药业集团股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告中详细阐述公司在经营过程中可能面临的各种风险及应对措施，敬请查阅本 报告"第三节 管理层讨论与分析"之"四、风险因素"。除此之外，公司无其他需要单独提示的 重大风险。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人于伟仕、主管会计工作负责人刘燕及会计机构负责人（会计主管人员）冯洁声 明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的公司未来计划、发展战略等前瞻性陈述，不构成公司对投 ...

悦康药业集团股份有限公司 2025 年度"提质增效重回报"行动方案的 半年度评估报告 2025 年上半年，公司研发投入为 20,904.36 万元，占营业收入的比例达到 17.91%，较上年同期增加 7.54 个百分点。目前，公司已建成了以核酸药物、细 胞与基因治疗药物、多肽药物、高端中药、高端化药、全流程 AI 药物研发等为 核心的十一大技术平台，储备了二十几项重点管线，具备了技术积累与管线布 局双重优势。截至 2025 年 6 月 30 日，公司研发项目合计 42 项，其中在研创新 药 21 项，在研仿制药及一致性评价项目 21 项，公司累计获得专利 349 项， 2025 上半年公司新申请专利 21 项，新获得专利 32 项。 为积极贯彻落实关于开展沪市公司"提质增效重回报"专项行动的倡议， 践行"以投资者为本"的上市公司发展理念，维护公司全体股东利益，悦康药 业集团股份有限公司（以下简称"公司"或"悦康药业"）于 2025 年 3 月 15 日 发布了《2025 年度"提质增效重回报"行动方案》。2025 年上半年，公司根据 "提质增效重回报"行动方案内容积极开展和落实相关工作，在保障投资者权 益、树 ...

证券代码：688658 证券简称：悦康药业 公告编号：2025-037 悦康药业集团股份有限公司 2025 年半年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 悦康药业集团股份有限公司（以下简称"公司"）董事会根据《上海证券 交易所科创板上市公司自律监管指引第 1 号——规范运作》及相关格式指引的 要求，编制了截至 2025 年 6 月 30 日的《2025 年半年度募集资金存放与使用情 况的专项报告》，报告具体内容如下： 一、募集资金基本情况 （一）实际募集资金的金额及到账情况 根据中国证券监督管理委员会于 2020 年 11 月 6 日出具的《关于同意悦康 药业集团股份有限公司首次公开发行股票注册的批复》（证监许可〔2020〕 2929 号文），公司于 2020 年 12 月向社会公开发行人民币普通股（A 股）9,000 万股，每股发行价为 24.36 元，应募集资金总额为人民币 219,240.00 万元，扣 除发行费用 17,488.45 万元（不含税）后的募集资金净额为人民币 ...

证券代码：688658 证券简称：悦康药业 公告编号：2025-038 悦康药业集团股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 9 月 2 日（星期二）至 2025 年 9 月 8 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过悦康药业集团股份 有限公司（以下简称"公司"）邮箱（irm@youcareyk.com）进行提问。公司将在 说明会上对投资者普遍关注的问题进行回答。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 会议召开时间：2025 年 9 月 9 日（星期二）10:00-11:00 会议召开地点：上海证券交易所上证路演中心 围内就投资者普遍关注的问题进行回答。 ...

Core Viewpoint - On August 27, Yuekang Pharmaceutical (688658) closed at 26.45 yuan, experiencing a significant drop of 16.82% in its closing price, with a trading volume of 6.87 billion yuan [1] Trading Performance - The stock's trading data indicated a turnover rate of 5.43% and a price fluctuation of 24.43% throughout the day [1] - The stock was listed on the trading board due to a closing price decline of 15% or more [1] Capital Flow - According to statistics from Securities Times and Data Treasure, the top five trading departments accounted for a total transaction volume of 4.07 billion yuan, with a buying transaction amount of 1.51 billion yuan and a selling transaction amount of 2.56 billion yuan, resulting in a net sell of 1.05 billion yuan [1] - Throughout the day, the stock experienced a net outflow of main funds amounting to 89.97 million yuan [1]

Proton Pump Inhibitor (PPI) Industry Overview - Proton pump inhibitors (PPIs) are the most potent acid-suppressing medications, widely used for treating acid-related diseases such as peptic ulcers and gastroesophageal reflux disease [1][2] - The Chinese oral PPI market has maintained a scale of over 10 billion yuan from 2018 to 2024, with strong market demand [1][6] - The market has shown volatility due to the implementation of volume-based procurement plans for several generic PPIs, leading to price declines despite increasing sales [1][6] Market Size and Trends - The market size for oral PPIs in China is projected to decline by 10.5% year-on-year in 2024, influenced by price reductions from collective procurement [1][6] - The market for PPIs used for peptic ulcers is valued at 4.8 billion yuan, while the market for those used for gastroesophageal reflux disease is valued at 1.8 billion yuan [6] Product Landscape - As of the end of 2024, there are seven PPI products approved for sale in China, with major products including Rabeprazole, Aplrazole, Esomeprazole, and Omeprazole, collectively holding over 87% market share [1][8] - Rabeprazole leads the market with a share of 27.6%, followed by Aplrazole at 23.7% [1][8] Competitive Landscape - The PPI industry is characterized by intense competition, with numerous companies involved in the production of various PPI products [1][9] - As of July 2025, there are 134 products of Lansoprazole, 106 products of Pantoprazole, and 440 products of Omeprazole produced by over 180 companies in China [1][9] - The leading company for Rabeprazole is Jichuan Pharmaceutical, holding over 30% market share, while AstraZeneca leads the Omeprazole market with a 17.8% share [1][9]